Atlas Venture Associates IX’s Coherus Oncology CHRS Stock Holding History

Atlas Venture Associates IX’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$2.13M	Buy	+568,408	New	+$2.63M	18.08%	2

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Atlas Venture Associates IX's CHRS Position: Q3 2023 in Review

Atlas Venture Associates IX opened a new position in Coherus Oncology (CHRS) in Q3 2023: 568,408 shares worth $2.13M. The stake represents 18.08% of the portfolio and ranks #2 among its holdings.

169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

Atlas Venture Associates IX held 568,408 shares of Coherus Oncology worth $2.13M as of Q3 2023.
Coherus Oncology was a new Atlas Venture Associates IX position in Q3 2023.
Coherus Oncology made up 18.08% of Atlas Venture Associates IX's portfolio in Q3 2023, its #2 holding.
169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Atlas Venture Associates IX's 13F filing for Q3 2023, filed 13 Nov 2023.